Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Eur Urol. 2019 Oct 20;77(3):333–341. doi: 10.1016/j.eururo.2019.09.036

Fig. 4 –

Fig. 4 –

Time to development of CRPC with combined localized and metastatic disease at presentation, stratified by mutation type, using the Kaplan-Meier method. Median time to CRPC: CDK12 24.6 mo, HRD 39.4 mo, TP53 30.8 mo, and other 42.2 mo. Overall p = 0.0056. CDK12 versus HRD p = 0.0063, CDK12 versus TP53 p = 0.0097, CDK12 versus other p = 0.0004, HRD versus TP53 p = 0.58, HRD versus other p = 0.7, and TP53 versus other p = 0.21. The greatest difference in mutations was in the CDK12 compared with the other cohort (24.6 vs 42.2 mo, p = 0.0004). The p values are based on log rank test.

CDK12 = cyclin-dependent kinase 12; CRPC = castration-resistant prostate cancer; HRD = homologous recombination deficiency.